Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, explains how utilizing genomic and immune single-cell analysis can give key insights into clinical markers of progression from smoldering multiple myeloma (SMM) to multiple myeloma. Dr Ghobrial highlights studies that have investigated single-cell sequencing of tumor cells in the bone marrow as well as circulating tumor cells, and emphasizes the vast amount of information that this can provide on disease progression and response to therapy. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
